Shots:

• Eurofarma to get exclusive license rights to develop and commercialize NLS-1 Pharma’s Nalazol Therapy in Central & South America and to take care of its regulatory approval
• In 2002- Mazindol was recalled from the US market based on its commercial sales (low sales). NLS-1 Pharma’s Mazindol control released formulation- Nalazol is expected to be marketed in H1’20
• Nolazol (mazindol- control release) is a non-amphetamine targeted as a C-4 treament for ADHD and is evaluated in P-II study and has shown efficacious results with no new safety signals

T Ref: Business Wire | Image : Twitter